Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.

A hybridoma cell stain and a monoclonal antibody secreted therefrom and application thereof belong to the technical field of prevention and treatment of Trichinella spiralis (T. spiralis). Aiming at the technical problem of how to specifically diagnose trichinellosis, the disclosure provides a hybridoma cell strain deposited under an accession number of CGMCC No. 18317. Tests show that the monoclonal antibody Ts-ZH68-2A4-Ab secreted by the hybridoma cell strain can compete with the positive serum of pigs infected with T. spiralis for binding to Ts-ZH68 antigen, and the recognition peptide is .sup.222GVDRSATCQGDSGGP.sup.236. The monoclonal antibody of the disclosure and the Ts-ZH68 protein B cell epitope polypeptide recognized by the monoclonal antibody can be used to prepare a reagent or a vaccine for diagnosing or preventing infection of T. spiralis, laying the foundation for establishment of a serological diagnosis method of T. spiralis.

[Problem] To provide a nucleic acid expected to be useful for treating crustacean allergy.

[Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Lit v 1, Lit v 4, and Lit v 3, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.

A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

The present disclosure provides systems and methods for delivering a gel to a surface. In one embodiment, the system may have a first vessel with a first low viscosity aqueous solution comprising a binder/crosslinking agent; and a second vessel with a second low viscosity aqueous solution comprising a gelling component. The separate first and second low viscosity aqueous solutions are sprayed onto a surface where the solutions mix forming a gel.

The present disclosure provides systems and methods for disrupting the outer membrane of an oocyst in solution and delivering the solution to an animal. The system includes a vessel containing unbroken oocysts in solution, an oocyst processing chamber, and a delivery outlet. The unbroken oocysts are moved from the vessel through the processing chamber and a portion of the oocyst membranes are disrupted releasing sporocysts, the resulting solution is moved from the processing chamber into the delivery outlet where the solution is delivered to an animal. Methods of vaccination, including vaccination against an Eimeria infection, are also provided.

The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations.

Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.

Isolated proteins from caligid copepods, polynucleotides encoding the same, and antigens and vaccines comprising the same, in particular for the treatment or prevention of caligid copepod infection in fish. Proteins are peroxiredoxin-2 (Prx-2), fructose bisphosphate aldolase (FBP); enolase, transitionally-controlled tumour protein homolog (TCTP) and triosephosphate isomerase (TIM).

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.